19p13.12 microdeletion syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:254346Q93.5
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

19p13.12 microdeletion syndrome (Orphanet: 254346) is a rare chromosomal disorder caused by a submicroscopic deletion on the short arm of chromosome 19 at band p13.12. This condition falls under the broader category of chromosomal deletions classified as Q93.5 in ICD-10. Because the deletion removes one or more genes in this chromosomal region, affected individuals typically present with a combination of developmental and neurological features. The syndrome is primarily characterized by intellectual disability, developmental delay (particularly speech and language delay), and variable dysmorphic facial features. Behavioral abnormalities, including features overlapping with autism spectrum disorder, have been reported in some patients. Additional clinical findings may include growth abnormalities, feeding difficulties in infancy, and seizures. The severity and range of symptoms can vary depending on the exact size and position of the deletion and which genes are encompassed. As with most microdeletion syndromes, there is no specific curative treatment. Management is supportive and multidisciplinary, focusing on early intervention programs including speech therapy, occupational therapy, physical therapy, and special educational support. Seizures, if present, are managed with standard antiepileptic medications. Regular developmental assessments and monitoring by a team of specialists including neurologists, geneticists, and developmental pediatricians are recommended to optimize outcomes for affected individuals.

Also known as:

Clinical phenotype terms— hover any for plain English:

Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for 19p13.12 microdeletion syndrome.

View clinical trials →

No actively recruiting trials found for 19p13.12 microdeletion syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the 19p13.12 microdeletion syndrome community →

No specialists are currently listed for 19p13.12 microdeletion syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to 19p13.12 microdeletion syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open 19p13.12 microdeletion syndromeForum →

No community posts yet. Be the first to share your experience with 19p13.12 microdeletion syndrome.

Start the conversation →

Latest news about 19p13.12 microdeletion syndrome

No recent news articles for 19p13.12 microdeletion syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about 19p13.12 microdeletion syndrome

What is 19p13.12 microdeletion syndrome?

19p13.12 microdeletion syndrome (Orphanet: 254346) is a rare chromosomal disorder caused by a submicroscopic deletion on the short arm of chromosome 19 at band p13.12. This condition falls under the broader category of chromosomal deletions classified as Q93.5 in ICD-10. Because the deletion removes one or more genes in this chromosomal region, affected individuals typically present with a combination of developmental and neurological features. The syndrome is primarily characterized by intellectual disability, developmental delay (particularly speech and language delay), and variable dysmorp

How is 19p13.12 microdeletion syndrome inherited?

19p13.12 microdeletion syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does 19p13.12 microdeletion syndrome typically begin?

Typical onset of 19p13.12 microdeletion syndrome is neonatal. Age of onset can vary across affected individuals.